Mankind Pharma to pro­vide high qual­ity & Af­forD­ABLE DI­AG­nos­tIC sEr­vICEs

Mankind Pharma col­lab­o­rates with Pathkind and San­jeev Vashishta would be co-pro­mot­ing a new ven­ture. Pathkind will also have mul­ti­ple col­lec­tion cen­ters in small towns and vil­lages

Rural & Marketing - - TECHNOLOGY -

Mankind Pharma, a USD 800 mil­lion

phar­ma­ceu­ti­cal com­pany, is for­ay­ing into Di­ag­nos­tics space with its new ven­ture Pathkind Di­ag­nos­tics. In the com­ing 4 years, the com­pany has a plan to in­vest Rs 305 crore in its new ven­ture, which will start its op­er­a­tion from Au­gust 2017.

As a part of the strat­egy, Pathkind would aim to reach out to the masses in tier 2/3 cities in India with the di­rect and clearcut ap­proach of pro­vid­ing eas­ily ac­ces­si­ble high qual­ity di­ag­nos­tics ser­vices at af­ford­able prices.

Mankind Pharma’s de­ci­sion of launch­ing the new Di­ag­nos­tics chain, Pathkind, is to fo­cus on organic growth. The com­pany is plan­ning to open 12 large labs, 20 rapid re­sponse labs and 150 col­lec­tion cen­tres in 12 months and will op­er­ate on a three-tier model. With a ref­er­ence lab in Gur­gaon, it will also have mul­ti­ple col­lec­tion cen­ters in small towns and vil­lages, which will be con­nected through the net­work of labs.

Ini­tially, the com­pany will start its op­er­a­tions from Ut­tar Pradesh and move to Ut­tarak­hand. To pro­mote this new ven­ture in the Di­ag­nos­tics space, Mankind has joined hands with San­jeev Vashishta.

San­jeev Vashishta, Manag­ing Direc­tor and CEO, Pathkind has been known for his abil­ity of con­nect­ing with peo­ple and for his po­ten­tial to turn around busi­nesses. Prior to join­ing Pathkind Labs, he suc­cess­fully man­aged run­ning op­er­a­tions (a clus­ter of hospi­tals) in the For­tis group with whom he was around for 11 years. He was also re­spon­si­ble for the dra­matic trans­for­ma­tion of SRL’s busi­ness in just 4 years.

Vashishta said,” Di­ag­nos­tics in­dus­try in India is grossly un­der-pen­e­trated. Given the fact that di­ag­no­sis costs frac­tion in com­par­i­son to the cost of treat­ment, and about 20 per­cent of the In­dian pop­u­la­tion has ever got a blood test done due to in­ac­ces­si­bil­ity/ig­no­rance, the vol­umes could be taken up sig­nif­i­cantly by just ed­u­cat­ing the pre­scribers (about new modal­i­ties) and the masses.

“There is a huge dearth of qual­ity ser­vice providers in India, as per the de­mand for the health­care/ di­ag­nos­tics ser­vices. Ven­tur­ing into di­ag­nos­tics is also a fi­nan­cially pru­dent de­ci­sion as di­ag­nos­tics model is as­set light, with low ges­ta­tion pe­riod and a lu­cra­tive RoI,” he added.

“At Pathkind, we are strongly com­mit­ted to serve at the grass root level so that the masses don’t have to travel miles in or­der to get them­selves di­ag­nosed."

“It will be our en­deav­our to pro­vide ac­cu­rate di­ag­nos­tics in the short­est pos­si­ble time. Fur­ther­more, as per the Na­tional Health Pol­icy 2017 the govt of India is com­mit­ted to give the much needed im­por­tance to Uni­ver­sal Health and the Gov­ern­ment in­tends to in­crease the health­care spend from a mea­gre 1 per­cent to 2.5 per­cent of GDP in the near fu­ture,”the Manag­ing Direc­tor said.

Pathkind aims are in line with the gov­ern­ment’s vi­sion to pro­vide qual­ity di­ag­nos­tics/ health­care ac­cess at an af­ford­able price.

San­jeev Vashishta Manag­ing Direc­tor & CEO, Pathkind

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.